Neurological muscular channelopathy due to a genetic potassium channel defect

Summary

Neurological muscular channelopathy due to a genetic potassium channel defect (MONDO:0957114) is a disease. A subtype of muscular channelopathy — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	neurological muscular channelopathy due to a genetic potassium channel defect
Mondo ID	MONDO:0957114
Orphanet	98741
UMLS	C5681685
MedGen	1842582
GARD	0019566
Is cancer (heuristic)	no

Disease family

This is a subtype of muscular channelopathy. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › nervous system disorder › neuromuscular disease › muscular channelopathy › neurological muscular channelopathy due to a genetic potassium channel defect

Related subtypes (11): Andersen-Tawil syndrome, Morvan syndrome, Thomsen and Becker disease, malignant hyperthermia of anesthesia, Isaac syndrome, RYR1-related myopathy, CNGB3-related retinopathy, SCN4A-related channelopathy, neurological muscular channelopathy due to a genetic sodium channel defect, neurological muscular channelopathy due to a genetic chloride channel defect, neurological muscular channelopathy due to a genetic calcium channel defect

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.